Company Overview of Philogen S.p.A.
Philogen S.p.A. is a biopharmaceutical company that targets cancer and other angiogenesis-associated diseases. It engages in developing immunocytokines, antibodies, and vascular targeting drugs; the discovery, GMP production, and clinical development of immunomodulatory biopharmaceuticals; developing antibody-based therapeutics specific for markers of angiogenesis; and developing DNA-encoded chemical libraries, small molecule drug conjugates, and antibody drug conjugates. It develops DARLEUKIN (L19-IL2), an immunostimulatory compound; TELEUKIN (F16-IL2), a human immunostimulatory antibody; FIBROMUN (L19-TNF), an anti-EDB human antibody; RADRETUMAB (L19-131I), a human vascular targeting antib...
Via Bellaria, 35
Sovicille, SI 53018
Founded in 1996
Key Executives for Philogen S.p.A.
Co-Founder, Chief Executive Officer, President and Director
Co-Founder, Director of IP & Licensing and Director
Co-Founder, President of the Scientific Advisory Board and Director
Vice President and Director
Compensation as of Fiscal Year 2015.
Philogen S.p.A. Key Developments
Boehringer Ingelheim, Philogen to Co-Develop Myeloid Leukaemia Treatments
Oct 13 15
Boehringer Ingelheim announced that it will collaborate with Philogen on the development of novel treatments for acute myeloid leukaemia. No financial terms were disclosed. Under their cooperation agreement, the companies will test "novel immunotherapy concepts" in one trial.
Philogen S.p.A. Presents at BIO-Europe 2015, Nov-02-2015
Oct 9 15
Philogen S.p.A. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.
Philogen S.p.A. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Philogen S.p.A. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries